Human Beta Cell Line Generation via Neonatal Pancreas Transduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating human beta cell lines from non-foetal pancreatic tissue are unreliable and not reproducible, limiting the availability of functional insulin-secreting cells for diabetes treatment and diagnosis.
Innovation Solution
A method involving sub-grafting of neonatal pancreatic tissues using lentiviral vectors expressing SV40 LargeT antigen and hTERT under the insulin promoter, followed by repeated enrichment and amplification steps to produce homogenous human beta cell lines capable of insulin secretion and glucose response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current methods are used to generate human beta cell lines from non-foetal pancreatic tissue, then the process is simpler, but the reliability and reproducibility are poor
Solution Approach 1:
The method segments the beta cell generation process into distinct stages: initial transduction of neonatal pancreatic tissue with SV40LT and hTERT, grafting into SCID mice to establish insulinomas, subsequent transduction with additional lentiviral vectors, and repeated enrichment cycles. Each stage builds upon the previous one, ensuring reliable production of functional beta cell lines through systematic progression rather than attempting the entire process in one step.
Solution Approach 2:
The method performs preliminary actions by first establishing insulinoma structures in SCID mice before attempting to generate functional beta cell lines. The initial transduction with SV40LT and hTERT creates a foundation of proliferating pancreatic cells that can then be further manipulated and enriched through subsequent steps, ensuring a reliable starting population for beta cell differentiation.
2Reliability
If embryonic stem cells are used as starting material, then self-renewal capacity is high, but the ability to produce functional human beta cells is limited
Solution Approach 1:
The method changes key parameters by using neonatal pancreatic tissue instead of embryonic stem cells as the starting material. This tissue source provides cells that are already committed to the pancreatic lineage and possess the capacity for functional insulin secretion. The introduction of hTERT extends cellular lifespan, while SV40LT provides proliferative capacity, creating a system that maintains both functionality and productivity.
Solution Approach 2:
SCID mice serve as an intermediary system that enables the production of functional human beta cells. The immunodeficient mice provide a living environment where transduced neonatal pancreatic cells can differentiate, proliferate, and form insulinoma structures that generate functional beta cells. This intermediary system bridges the gap between in vitro transduction and the production of clinically relevant functional cells.
3Adaptability or versatility
If rodent beta cell lines are used, then detailed study of beta cell biology is enabled, but applicability to human diagnosis or therapy is limited
Solution Approach 1:
Instead of using rodent cells and attempting to translate findings to humans, the method inverts the approach by using human neonatal pancreatic tissue as the starting material. This ensures that the resulting beta cell lines are human in origin and directly applicable to human diagnosis and therapy, while still enabling detailed biological study through the controlled in vivo and in vitro systems.
4Reliability
If adult pancreatic cells are used, then ethical concerns are avoided, but the cells are refractory to transformation
Solution Approach 1:
The method changes the developmental stage parameter by using neonatal pancreatic tissue (from infants under 1 year old) instead of adult tissue. Neonatal cells retain greater proliferative and transformation potential compared to adult cells, while still representing post-foetal human tissue that avoids embryonic ethical issues. The combination of SV40LT and hTERT further enhances transformation capability in this neonatal cell population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method generates functional human beta cell lines that can normalize blood glucose levels in diabetic mice, providing a reliable source for clinical use and diabetes diagnosis, and can be amplified for therapeutic and commercial purposes.
Implementation Method 1
transducing and co-transducing the neonatal human pancreas cells obtained in step a) with i) a lentiviral vector expressing SV40 LargeT antigen under the control of the insulin promoter or ii) with a lentiviral vector expressing SV40 LargeT antigen under the control of the insulin promoter and a lentiviral vector expressing hTERT under the control of the insulin promoter
Implementation Method 2
dissociating neonatal human pancreatic tissue with collagenase in order to obtain neonatal human pancreas cells
Implementation Method 3
endocrine islets composed of cells that produce hormones such as insulin (beta cells)... allowing the transduced pancreas cells to develop insulinoma-like structures, wherein neonatal human pancreases cells in insulinoma-like structures have differentiated in insulin-producing pancreatic beta cells
Data Source
Figure 1~2
Figure 3
AI summary
The present invention relates to a method for preparing commercial scale quantities of human functional beta cells and to the establishment of cell lines from non- foetal pancreatic tissues. It also relates to a method of diagnosis using beta cell tumors or cells derived thereof. The method comprises sub-transplantation procedure to enrich the graft in proliferating beta cells, allowing to generate human Beta cell lines. Such lines express, produce and secrete insulin upon glucose stimulation. They have a gene expression profile that resembles to adult beta cells. In addition, the human beta cell lines are able to normalize glycemia of diabetic mice when transplanted, demonstrating their insulin secretion capabilities.